{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2013"],"condition":["metastatic colorectal cancer"],"disease":["Metastatic Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2646684"],"location":["Japan"],"study_start_month":["1"],"repository":["ECRIN MDR"],"study_status":["Active, not recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Analysis of differentiation of antiEGFR antibody in the 1st line chemotherapy with mFOLFOX6 in RAS-wild metastatic colorectal cancer.","description":"Interventions: mFOLFOX6+cetuximab or panitumumab\nPrimary outcome(s): response rate\nStudy Design: Single arm Non-randomized","dates":{"creation":"2013-01-15"},"accession":"2646684","cross_references":{"Japan Primary Registries Network":["JPRN-UMIN000031535"]}}